Simply Wall StEditas Medicine Announces Third Quarter 2017 Results and UpdateGuruFocus.com… disease and beta thalassemia. In data to be presented at ASH, we will demonstrate high levels of gene disruption of adult human hematopoietic stem cells with … Continue reading
Weekly RegisterEditas Medicine Announces Third Quarter 2017 Results and UpdateMarkets Insider… disease and beta thalassemia. In data to be presented at ASH, we will demonstrate high levels of gene disruption of adult human hematopoietic stem cells wi… Continue reading
BangaloreWeekly |
Editas Medicine Announces Third Quarter 2017 Results and Update
Nasdaq … disease and beta thalassemia. In data to be presented at ASH, we will demonstrate high levels of gene disruption of adult human hematopoietic stem cells with CRISPR/Cpf1 and efficient targeted integration at the beta-hemoglobin locus with CRISPR/Cas9. Contrasting Editas Medicine (NASDAQ:EDIT) & Oramed Pharmaceuticals (ORMP)TrueBlueTribune Zacks’ 7 Best Strong Buys for 2018Zacks.com |
|
Chile seeks to regulate storage of stem cells
Xinhua SANTIAGO, Nov. 7 (Xinhua) — Chile’s health minister, Carmen Castillo, announced Tuesday that the government is preparing a law to regulate the storage of stem cells. This matter has become a hot topic in the country after one private clinic storing … |
|
Immunotherapy Biotech Poised to Soar
Minyanville.com While immunotherapy is an exciting area for investing, the blue-chip biopharmaceutical companies are mega-caps with only limited room for growth. They’re rushing into immunotherapy to fend off the revenue cliff they face when patents for their … |
Epidermolysis Bullosa News |
Krystal Biotech Receives $700K Equity-Based Award to Develop Gene Therapy for DEB
Epidermolysis Bullosa News “Our lead product candidate KB103, based on our proprietary gene therapy platform, is designed to be an ‘off-the-shelf’ topical product to treat dystrophic epidermolysis bullosa (DEB). We currently expect to file an Investigational New Drug Application … |